About this study Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase ...

Adding ibrutinib to rituximab improved outcomes in patients with previously untreated FL who were ineligible for CIT.